Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dezapelisib + Itacitinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dezapelisib | INCB040093 | PIK3CD inhibitor 27 | Dezapelisib (INCB040093) is a specific inhibitor of PIK3CD, which blocks PI3K/AKT signaling to prevent cell proliferation (PMID: 29695516, PMID: 29127109). | |
Itacitinib | INCB039110|INCB-039110|INCB 039110 | JAK1 Inhibitor 9 | Itacitinib (INCB039110) is a selective inhibitor of Janus kinase 1 (JAK1), which may inhibit cell proliferation (PMID: 25605813, PMID: 32861662). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01905813 | Phase I | Dezapelisib + Itacitinib Dezapelisib | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |